Celmatix Revenue and Competitors
Estimated Revenue & Valuation
- Celmatix's estimated annual revenue is currently $4.8M per year.
- Celmatix's estimated revenue per employee is $155,000
Employee Data
- Celmatix has 31 Employees.
- Celmatix grew their employee count by -6% last year.
Celmatix's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | COO / CFO | Reveal Email/Phone |
3 | COO / CFO | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP Biological Sciences | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | General Counsel | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Director Clinical Research Operations | Reveal Email/Phone |
10 | Senior Manager, Medical Communications | Reveal Email/Phone |
Celmatix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Celmatix?
Celmatix is a preclinical-stage women's health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. For more information visit www.celmatix.com.
keywords:N/AN/A
Total Funding
31
Number of Employees
$4.8M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celmatix News
... a new biotech startup called Celmatix wants to improve women's ovarian ... life, according to Piraye Beim, founder and CEO of Celmatix.
Celmatix plans on starting clinical trials of its menopause-delaying drug in 2023. The trials will begin with women undergoing chemotherapy,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.6M | 31 | -16% | N/A |
#2 | $6.2M | 31 | -51% | N/A |
#3 | $5.1M | 31 | 19% | N/A |
#4 | $3.6M | 31 | N/A | N/A |
#5 | $3.6M | 31 | N/A | N/A |